Did the window for US initial public offerings by biotechnology companies suddenly slammed shut in late November? Now that everyone's back at work after the Thanksgiving holiday, that appears to be the case, and it doesn't look like the biotech IPO window will reopen anytime soon.
The IPO market peaked in the first half of 2015 with returns for drug developers that went public between January...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?